BeOne Medicines Announces Third Quarter 2026 Financial Results and Business
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
• Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year
• BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior year
• Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarter
• Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion
SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026.
“Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization.”
* For an explanation of our use of non-GAAP financial measures, refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.
totaled $1.9 billion for the third quarter of 2026, representing growth of 33% compared to the prior-year period.
• BRUKINSA: Global sales totaled $1.4 billion for the third quarter of 2026, representing growth of 34% compared to the prior-year period; U.S. sales of BRUKINSA totaled $1.0 billion in the third quarter of 2026, representing growth of 36% compared to the prior-year period.
• TEVIMBRA (tislelizumab): Global sales totaled $243 million in the third quarter of 2026, representing growth of 28% compared to the prior-year period.
• Amgen in-licensed products: Global sales totaled $167 million in the third quarter of 2026, representing growth of 26% compared to the prior-year period.
as a percentage of global product sales for the third quarter of 2026 was 88%, compared to 86% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company’s portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA, which was offset by a non-cash intangible asset impairment charge of $22 million associated with our decision to discontinue promotion of POBEVCY. On an adjusted basis, which does not include depreciation and amortization, or the impairment charge, gross margin as a percentage of product sales increased to 90%, from 86% in the comparable period of the prior year.
The following table summarizes operating expenses for the third quarter of 2026:
The following table summarizes operating expenses for the year-to-date period ended September 30, 2026, and 2025:
increased for the third quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to advancing early clinical programs into late stage and preclinical programs into the clinic.
Selling, General and Administrative (SG&A) Expenses increased for the third quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment to support commercial growth.
GAAP net income for the third quarter of 2026 was $385 million, an increase of $260 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage. Adjusted net income was $539 million, an increase of $235 million over the prior-year period.
For the third quarter of 2026, basic and diluted earnings per share were $0.26 and $0.25 per share and $3.38 and $3.28 per American Depositary Share (ADS), respectively, compared to $0.09 and $0.08 per share and $1.13 and $1.09 per ADS in the prior-year period. On an adjusted basis, basic and diluted earnings per share was $0.36 and $0.35 per share and $4.74 and $4.59 per ADS, respectively, compared to $0.21 and $0.20 per share and $2.76 and $2.65 per ADS in the prior- year period.
for the third quarter of 2026 was $474 million, representing an increase of $119 million over the prior-year period.
For further details on BeOne’s Third Quarter 2026 Financial Statements, please see BeOne’s Quarterly Report on Form 10-Q for the third quarter of 2026 filed with the U.S. Securities and Exchange Commission.
Prior FY 2026 Guidance Current FY 2026 Guidance1 Total revenue $6.6B - $6.8B $6.9B - $7.0B GAAP gross margin % High-80% range High-80% range GAAP operating expenses2 $4.8B - $5.0B $4.9B - $5.0B (combined R&D and SG&A) GAAP operating income2 $1.0B - $1.1B $1.2B - $1.3B Non-GAAP operating $1.7B - $1.8B $1.9B - $2.0B income2,3
2 Does not assume any potential new, material business development activity or unusual/non-recurring items.
3 Non-GAAP operating income is a financial measure that excludes from the corresponding GAAP measure costs related to share-based compensation, depreciation and amortization expense. Guidance assumes that Non-GAAP expenses track overall expense growth.
BeOne’s total revenue guidance for full year 2026 of $6.9 billion to $7.0 billion reflects performance through the third quarter and the Company’s expectations for the remainder of the year. Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and productivity improvements. Guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth.
The Company is providing the following additional guidance on items impacting net income and earnings per ADS:
• Other income (expense): Estimated range of $25 million to $50 million in expense, includes interest amortization from the Royalty Pharma arrangement.
: Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized. The Company continues to evaluate and assess the magnitude but expects the reversal will occur in the fourth quarter of 2026. See Form 10-Q for additional updates.
• Diluted ADS outstanding: The Company expects diluted ADSs outstanding of approximately 118 million.
• Received U.S. Food and Drug Administration (FDA) Priority Review designation for the Phase 3 MANGROVE filing.
• 29 abstracts accepted for presentation at the American Society of Hematology (ASH) 2026 Annual Meeting, including interim analysis results from the Phase 3 MANGROVE study in first-line mantle cell lymphoma (MCL) to be presented during the Plenary Scientific Session.
• Received Japan regulatory approval for the treatment of adult patients with first-line nasopharyngeal cancer.
ZIIHERA (zanidatamab) for which BeOne holds commercialization rights in select markets
• Presented Phase 3 survival data reinforcing benefit of ZIIHERA-containing regimens in first-line HER2+ gastroesophageal adenocarcinoma (GEA) at the European Society for Medical Oncology Congress 2026 (ESMO 2026).
• Received U.S. Food and Drug Administration (FDA) approval for TEVIMBRA-based regimen for first-line HER2+ GEA.
• Tacabrutideg (BTK CDAC): Pivotal Phase 2 portion of CaDAnCe-101 met its primary endpoint of overall response rate in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
• BG-75202 (KAT6 A/B inhibitor): First patient enrolled into monotherapy cohort for the Phase 1 study for the treatment of adult patients with acute myeloid leukemia.
◦ Received Orphan Drug Designation from the European Commission and awarded Innovation Passport, enabling entry to the UK's Innovative Licensing and Access Pathway, in hepatocellular carcinoma (HCC).
• BG-85738 (RAS ONi): First patient enrolled in the Phase 1 study of advanced solid tumors with RAS mutations.
◦ Received FDA Fast Track Designation for the treatment of patients with advanced or metastatic CEA-high non-small cell lung cancer whose disease has progressed following prior systemic therapy.
• BGB 58067 (MTA-cooperative PRMT5 inhibitor): Disclosed first clinical data at ESMO 2026.
• BG-C9074 (B7-H4 ADC): Initiated Starstone-301 Phase 3 study in combination with bevacizumab for the treatment of adult patients with first-line ovarian cancer in maintenance setting.
Programs Milestones Timing •Regulatory submission in Japan BRUKINSA for the treatment of adult Q4 2026 patients with first-line MCL. •China regulatory action for the treatment of adult patients TEVIMBRA with first-line HER2-positive 1H 2027 GEA in combination with ZIIHERA and chemotherapy. •China regulatory action for the treatment of adult patients ZIIHERA with first-line HER2-positive 1H 2027 GEA in combination with chemotherapy, with or without TEVIMBRA. •Phase 2 potential submission Tacabrutideg(BGB-16673) for the treatment of adult Mid 2027 patients with R/R CLL. •CaDAnCe-306: Phase 3 study initiation 1H 2027 for R/R CLL in combination with BEQALZI BGB-B2033 •GroundBBreaker-301 Phase 3 (GPC3x4-1BB bispecific study initiation in second-line Q4 2026 antibody) or later hepatocellular carcinoma. •GroundBBreaker-201 potentially pivotal single-arm Phase 2 study initiation in Q4 2026 second-line or later hepatocellular carcinoma. •GroundBBreaker-302 pivotal Phase 3 study initiation in 1H 2027 first-line hepatocellular carcinoma
• Announced a multi-part collaboration with Revolution Medicines, including a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets.
• Announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening the Company’s U.S manufacturing footprint.
• Announced the renewal of a partnership with the BeOne Care Foundation and The Max Foundation, a leading global health nonprofit organization, to expand access to BRUKINSA for the treatment of adult patients with CLL in low- and middle- income countries through 2028.
The Company’s earnings conference call for the third quarter 2026 will be broadcast via webcast at 8:00 a.m. ET on Thursday, November 5, 2026, and will be accessible through the Investors section of BeOne’s website at www.beonemedicines.com. Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available.
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: BeOne’s continued rapid global growth and leadership in hematology; future catalysts for BeOne’s business; BeOne’s full year 2026 guidance; BeOne’s expectations regarding certain valuation allowances; BeOne’s expectations regarding continued global expansion and investment to support growth; upcoming R&D milestones to be achieved by BeOne; the timing of clinical and regulatory developments and data readouts; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.
Investor Contact Media Contact Liza Heapes Meredith Ferguson +1 857-302-5663 +1 216-338-3797 [email protected] [email protected]
(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)
BeOne provides certain non-GAAP financial measures, including Adjusted Cost of Sales- Product, Adjusted Operating Expenses, Adjusted Income from Operations, Adjusted Income Tax Expense, Adjusted Net Income, Adjusted Earnings Per Share, Free Cash Flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne’s operating performance. Adjustments to BeOne’s GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne’s operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne’s management uses for planning and forecasting purposes and measuring BeOne’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.
1. Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the relevant tax jurisdiction. Please note that the Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects.
Reconciliation of GAAP Operating Income Guidance to Non-GAAP Operating Income Guidance for Full Year 2026 -Unaudited GAAP operating income 1,200,000 — 1,300,000 Plus: Adjustments to arrive at 700,000 — 700,000 Non-GAAP1 Non-GAAP operating income 1,900,000 — 2,000,000
1. The non-GAAP adjustments are based on actual results through the first nine months of 2026 and best available information at this time related to similar items for the remainder of the year.
Full text with the tables
Exhibit 99.1
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business
Updates
• Total global revenues of $1.9 billion for the third quarter, an increase of
34% from the prior year
• BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,
an increase of 34% from the prior year
• Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the
third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarter
• Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating
income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0
billion
SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX:
06160; SSE: 688235), a global oncology company, today announced financial
results and corporate updates from the third quarter of 2026.
John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:
“Our strong third quarter results and raised full-year guidance reflect
continued rapid global growth and leadership in hematology, anchored by our
foundational BTK inhibitor BRUKINSA, which drives powerful and sustained
responses in patients, and now joined by our next-generation BCL2 inhibitor
BEQALZI. We look forward to multiple catalysts in the coming months from one of
the deepest pipelines in oncology, spanning hematology and solid tumors,
accelerated by our differentiated capabilities in R&D, manufacturing, and
commercialization.”
(Amounts in thousands of U.S. dollars and unaudited)
Th… Ni…
Mo… Mo…
En… Se… % En… S… %
20… 30, 20… Ch… 20… 3… 20… Ch…
──────────────────────────────────────────────────────────────────────────────
N…
p… $ 1,… $ 1,… 33 % $ 5… $ 3… 32 %
r…
O… $ 34… $ 17… 1… % $ 8… $ 3… 1… %
r…
T… $ 1,… $ 1,… 34 % $ 5… $ 3… 33 %
r…
G…
i… $ 41… $ 16… 1… % $ 9… $ 2… 2… %
f…
o…
A…
i… $ 61… $ 34… 79 % $ 1… $ 7… 1… %
f…
o…
G…
n… $ 38… $ 12… 2… % $ 8… $ 2… 2… %
i…
A…
n… $ 53… $ 30… 77 % $ 1… $ 6… 96 %
i…
G…
b…
E… $ 3.… $ 1.… 1… % $ 7… $ 2… 2… %
p…
A…
A…
b…
E… $ 4.… $ 2.… 72 % $ 1… $ 6… 90 %
p…
A…
G…
d…
E… $ 3.… $ 1.… 2… % $ 7… $ 1… 2… %
p…
A…
A…
d…
E… $ 4.… $ 2.… 73 % $ 1… $ 6… 90 %
p…
A…
F…
C… $ 47… $ 35… 34 % $ 1… $ 5… 90 %
F…
* For an explanation of our use of non-GAAP financial measures, refer to the
“Note Regarding Use of Non-GAAP Financial Measures” section later in this press
release and for a reconciliation of each non-GAAP financial measure to the most
comparable GAAP measures, see the table at the end of this press release.
Exhibit 99.1
Third Quarter 2026 Financial Results
Product Revenue
totaled $1.9 billion for the third quarter of 2026, representing growth of 33%
compared to the prior-year period.
• BRUKINSA: Global sales totaled $1.4 billion for the third quarter of 2026,
representing growth of 34% compared to the prior-year period; U.S. sales of
BRUKINSA totaled $1.0 billion in the third quarter of 2026, representing growth
of 36% compared to the prior-year period.
• TEVIMBRA (tislelizumab): Global sales totaled $243 million in the third
quarter of 2026, representing growth of 28% compared to the prior-year period.
• Amgen in-licensed products: Global sales totaled $167 million in the third
quarter of 2026, representing growth of 26% compared to the prior-year period.
Gross Margin
as a percentage of global product sales for the third quarter of 2026 was 88%,
compared to 86% in the prior-year period on a GAAP basis. The gross margin
percentage increased due to a proportionally higher sales mix of global BRUKINSA
compared to other products in the Company’s portfolio. Gross margin also
benefited from productivity improvements resulting in lower costs for both
BRUKINSA and TEVIMBRA, which was offset by a non-cash intangible asset
impairment charge of $22 million associated with our decision to discontinue
promotion of POBEVCY. On an adjusted basis, which does not include depreciation
and amortization, or the impairment charge, gross margin as a percentage of
product sales increased to 90%, from 86% in the comparable period of the prior
year.
Operating Expenses
The following table summarizes operating expenses for the third quarter of 2026:
(u…
in
th…
ex… Q3 Q3 % Q3 Q3 %
pe… GA… 20… 2025 Ch… Non… 20… 2025 Ch…
──────────────────────────────────────────────────────────────────────────────
R…
a… $ 66… $ 523… 26 % $ 58… $ 445… 31 %
d…
S…
g… $ 59… $ 528… 12 % $ 50… $ 434… 16 %
a…
a…
T…
o… $ 1,… $ 1,0… 19 % $ 1,… $ 880… 24 %
e…
The following table summarizes operating expenses for the year-to-date period
ended September 30, 2026, and 2025:
(u…
in
th… Q3 Q3 Q3 Q3
ex… YTD YTD % YTD YTD %
pe… GA… 20… 2025 Ch… Non… 20… 2025 Ch…
──────────────────────────────────────────────────────────────────────────────
R…
a… $ 1,… $ 1,5… 19 % $ 1,… $ 1,3… 21 %
d…
S…
g… $ 1,… $ 1,5… 14 % $ 1,… $ 1,2… 16 %
a…
a…
T…
o… $ 3,… $ 3,0… 16 % $ 3,… $ 2,5… 19 %
e…
Research and Development (R&D) Expenses
increased for the third quarter of 2026 compared to the prior-year period on
both a GAAP and adjusted basis due to advancing early clinical programs into
late stage and preclinical programs into the clinic.
Selling, General and Administrative (SG&A) Expenses increased for the third
quarter of 2026 compared to the prior-year period on both a GAAP and adjusted
basis due to continued investment to support commercial growth.
Net Income and Basic/Diluted Earnings Per Share
GAAP net income for the third quarter of 2026 was $385 million, an increase of
$260 million over the prior-year period, primarily attributable to revenue
growth and improved operating leverage. Adjusted net income was $539 million, an
increase of $235 million over the prior-year period.
Exhibit 99.1
For the third quarter of 2026, basic and diluted earnings per share were $0.26
and $0.25 per share and $3.38 and $3.28 per American Depositary Share (ADS),
respectively, compared to $0.09 and $0.08 per share and $1.13 and $1.09 per ADS
in the prior-year period. On an adjusted basis, basic and diluted earnings per
share was $0.36 and $0.35 per share and $4.74 and $4.59 per ADS, respectively,
compared to $0.21 and $0.20 per share and $2.76 and $2.65 per ADS in the prior-
year period.
Free Cash Flow
for the third quarter of 2026 was $474 million, representing an increase of $119
million over the prior-year period.
For further details on BeOne’s Third Quarter 2026 Financial Statements, please
see BeOne’s Quarterly Report on Form 10-Q for the third quarter of 2026 filed
with the U.S. Securities and Exchange Commission.
Full Year 2026 Guidance
BeOne’s financial guidance is summarized below:
Prior FY 2026 Guidance Current FY 2026
Guidance1
Total revenue $6.6B - $6.8B $6.9B - $7.0B
GAAP gross margin % High-80% range High-80% range
GAAP operating
expenses2 $4.8B - $5.0B $4.9B - $5.0B
(combined R&D and
SG&A)
GAAP operating income2 $1.0B - $1.1B $1.2B - $1.3B
Non-GAAP operating $1.7B - $1.8B $1.9B - $2.0B
income2,3
1 Assumes November 1, 2026 foreign exchange rates.
2 Does not assume any potential new, material business development activity or
unusual/non-recurring items.
3 Non-GAAP operating income is a financial measure that excludes from the
corresponding GAAP measure costs related to share-based compensation,
depreciation and amortization expense. Guidance assumes that Non-GAAP expenses
track overall expense growth.
BeOne’s total revenue guidance for full year 2026 of $6.9 billion to $7.0
billion reflects performance through the third quarter and the Company’s
expectations for the remainder of the year. Gross margin percentage is expected
to be in the high-80% range and includes the impact of product mix and
productivity improvements. Guidance for combined operating expenses on a GAAP
basis includes expectations of investment to support growth.
The Company is providing the following additional guidance on items impacting
net income and earnings per ADS:
• Other income (expense): Estimated range of $25 million to $50 million in
expense, includes interest amortization from the Royalty Pharma arrangement.
•
Income tax outlook
: Earnings may provide sufficient positive evidence to reverse certain valuation
allowances in 2026, resulting in a material tax benefit when recognized. The
Company continues to evaluate and assess the magnitude but expects the reversal
will occur in the fourth quarter of 2026. See Form 10-Q for additional updates.
• Diluted ADS outstanding: The Company expects diluted ADSs outstanding of
approximately 118 million.
Third Quarter 2026 Business Highlights
Core Marketed Products
BRUKINSA (zanubrutinib)
• Received U.S. Food and Drug Administration (FDA) Priority Review designation
for the Phase 3 MANGROVE filing.
• Completed Phase 3 MANGROVE regulatory submissions in the EU and China.
• 29 abstracts accepted for presentation at the American Society of Hematology
(ASH) 2026 Annual Meeting, including interim analysis results from the Phase 3
MANGROVE study in first-line mantle cell lymphoma (MCL) to be presented during
the Plenary Scientific Session.
BEQALZI (sonrotoclax)
• 10 abstracts accepted for presentation at ASH 2026.
TEVIMBRA (tislelizumab)
• Received Japan regulatory approval for the treatment of adult patients with
first-line nasopharyngeal cancer.
Exhibit 99.1
ZIIHERA (zanidatamab) for which BeOne holds commercialization rights in select
markets
• Presented Phase 3 survival data reinforcing benefit of ZIIHERA-containing
regimens in first-line HER2+ gastroesophageal adenocarcinoma (GEA) at the
European Society for Medical Oncology Congress 2026 (ESMO 2026).
• Received U.S. Food and Drug Administration (FDA) approval for TEVIMBRA-based
regimen for first-line HER2+ GEA.
Select Clinical-Stage Programs
Hematology
• 6 Tacabrutideg abstracts accepted for presentation at ASH 2026.
• Tacabrutideg (BTK CDAC): Pivotal Phase 2 portion of CaDAnCe-101 met its
primary endpoint of overall response rate in patients with relapsed/refractory
chronic lymphocytic leukemia (CLL).
• BG-75202 (KAT6 A/B inhibitor): First patient enrolled into monotherapy cohort
for the Phase 1 study for the treatment of adult patients with acute myeloid
leukemia.
Gastrointestinal Cancers
• BGB-B2033 (GPC3x4-1BB bispecific antibody):
◦ Updated data presented at ESMO 2026.
◦ Received Orphan Drug Designation from the European Commission and awarded
Innovation Passport, enabling entry to the UK's Innovative Licensing and Access
Pathway, in hepatocellular carcinoma (HCC).
• BG-85738 (RAS ONi): First patient enrolled in the Phase 1 study of advanced
solid tumors with RAS mutations.
Lung Cancer
• BG-C477 (CEA ADC):
◦ Disclosed first clinical data at ESMO 2026.
◦ Received FDA Fast Track Designation for the treatment of patients with
advanced or metastatic CEA-high non-small cell lung cancer whose disease has
progressed following prior systemic therapy.
• BGB 58067 (MTA-cooperative PRMT5 inhibitor): Disclosed first clinical data at
ESMO 2026.
Breast and Gynecological Cancers
• BG-C9074 (B7-H4 ADC): Initiated Starstone-301 Phase 3 study in combination
with bevacizumab for the treatment of adult patients with first-line ovarian
cancer in maintenance setting.
Anticipated R&D Milestones
Programs Milestones Timing
•Regulatory submission in Japan
BRUKINSA for the treatment of adult Q4 2026
patients with first-line MCL.
•China regulatory action for
the treatment of adult patients
TEVIMBRA with first-line HER2-positive 1H 2027
GEA in combination with ZIIHERA
and chemotherapy.
•China regulatory action for
the treatment of adult patients
ZIIHERA with first-line HER2-positive 1H 2027
GEA in combination with
chemotherapy, with or without
TEVIMBRA.
•Phase 2 potential submission
Tacabrutideg(BGB-16673) for the treatment of adult Mid 2027
patients with R/R CLL.
•CaDAnCe-306: Phase 3 study
initiation 1H 2027
for R/R CLL in combination
with BEQALZI
BGB-B2033 •GroundBBreaker-301 Phase 3
(GPC3x4-1BB bispecific study initiation in second-line Q4 2026
antibody) or later hepatocellular
carcinoma.
•GroundBBreaker-201
potentially pivotal
single-arm Phase 2 study
initiation in Q4 2026
second-line or later
hepatocellular
carcinoma.
•GroundBBreaker-302 pivotal
Phase 3
study initiation in 1H 2027
first-line
hepatocellular carcinoma
Exhibit 99.1
Corporate Updates
• Announced a multi-part collaboration with Revolution Medicines, including a
clinical collaboration to evaluate drug combinations incorporating select
clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four
clinical RAS(ON) inhibitors, and a separate regional rights agreement granting
BeOne exclusive development and commercialization rights to these Revolution
Medicines assets in select Asian markets.
• Announced a voluntary agreement with the U.S. Government to expand access to
innovative cancer medicines for American patients while strengthening the
Company’s U.S manufacturing footprint.
• Announced the renewal of a partnership with the BeOne Care Foundation and The
Max Foundation, a leading global health nonprofit organization, to expand access
to BRUKINSA for the treatment of adult patients with CLL in low- and middle-
income countries through 2028.
BeOne’s Earnings Results Webcast
The Company’s earnings conference call for the third quarter 2026 will be
broadcast via webcast at 8:00 a.m. ET on Thursday, November 5, 2026, and will be
accessible through the Investors section of BeOne’s website at
www.beonemedicines.com. Supplemental information in the form of a slide
presentation, transcript of prepared remarks, and a replay of the webcast will
also be available.
About BeOne
BeOne Medicines is a global oncology company that is discovering and developing
innovative treatments for cancer patients worldwide. With a portfolio spanning
hematology and solid tumors, BeOne is expediting development of its diverse
pipeline of novel therapeutics through its internal capabilities and
collaborations. The Company has a growing global team spanning six continents
who are driven by scientific excellence and exceptional speed to reach more
patients than ever before.
To learn more about BeOne, please visit www.beonemedicines.com and follow us on
LinkedIn, X, Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including statements regarding: BeOne’s continued rapid global growth and
leadership in hematology; future catalysts for BeOne’s business; BeOne’s full
year 2026 guidance; BeOne’s expectations regarding certain valuation allowances;
BeOne’s expectations regarding continued global expansion and investment to
support growth; upcoming R&D milestones to be achieved by BeOne; the timing of
clinical and regulatory developments and data readouts; and BeOne’s plans,
commitments, aspirations and goals under the caption “About BeOne.” Actual
results may differ materially from those indicated in the forward-looking
statements as a result of various important factors, including BeOne’s ability
to demonstrate the efficacy and safety of its drug candidates; the clinical
results for its drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may affect the
initiation, timing and progress of clinical trials and marketing approval;
BeOne’s ability to achieve commercial success for its marketed medicines and
drug candidates, if approved; BeOne’s ability to obtain and maintain protection
of intellectual property for its medicines and technology; BeOne’s reliance on
third parties to conduct drug development, manufacturing, commercialization, and
other services; BeOne’s limited experience in obtaining regulatory approvals and
commercializing pharmaceutical products; BeOne’s ability to obtain additional
funding for operations and to complete the development of its drug candidates
and achieve and maintain profitability; and those risks more fully discussed in
the section entitled “Risk Factors” in BeOne’s most recent periodic report filed
with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions
of potential risks, uncertainties, and other important factors in BeOne’s
subsequent filings with the SEC. All information in this press release is as of
the date of this press release, and BeOne undertakes no duty to update such
information unless required by law. BeOne’s financial guidance is based on
estimates and assumptions that are subject to significant uncertainties.
Investor Contact Media Contact
Liza Heapes Meredith Ferguson
+1 857-302-5663 +1 216-338-3797
[email protected] [email protected]
Exhibit 99.1
Condensed Consolidated Statements of Operations (U.S. GAAP)
(Amounts in thousands of U.S. dollars, except for shares, American Depositary
Shares (ADSs), per share and per ADS data)
Three Nine
Months Months
Ended Ended
Septem… Septe…
30, 30,
2026 2026
Reve… (Unaud… 2025 (Unau… 2025
──────────────────────────────────────────────────────────────────────────────
Prod…
reve… $ 1,855… $ 1,395,… $ 5,022,… $ 3,805…
net
Other 34,758 17,271 86,144 39,244
reve…
Total 1,889… 1,412,… 5,108,… 3,844…
reve…
Cost
of
sales 216,8… 196,510 558,641 526,1…
-
prod…
Gross 1,672… 1,215,… 4,549,… 3,318…
prof…
Oper…
expe…
Rese…
and 660,7… 523,662 1,814,… 1,530…
deve…
Sell…
gene… 593,4… 528,998 1,741,… 1,526…
and
admi…
Total
oper… 1,254… 1,052,… 3,556,… 3,056…
expe…
Inco…
from 418,6… 163,114 993,624 262,1…
oper…
Inte… 33,663 19,393 89,227 43,735
inco…
Inte… -42,4… -16,364 -115,0… -31,3…
expe…
Other
inco… 429 -18,979 14,216 -6,862
(exp…
net
Inco…
befo… 410,3… 147,164 982,034 267,6…
inco…
taxes
Inco…
tax 25,654 22,323 132,964 47,182
expe…
Net $ 384,7… $ 124,841 $ 849,070 $ 220,4…
inco…
Earn…
per
share
Basic $ 0.26 $ 0.09 $ 0.58 $ 0.16
Dilu… $ 0.25 $ 0.08 $ 0.56 $ 0.15
Weig…
shar… 1,478… 1,432,… 1,457,… 1,410…
outs…
Weig…
shar… 1,524… 1,488,… 1,511,… 1,465…
outs…
Earn…
per
Amer…
Depo…
Share
(“AD…
Basic $ 3.38 $ 1.13 $ 7.58 $ 2.03
Dilu… $ 3.28 $ 1.09 $ 7.30 $ 1.96
Weig…
ADSs 113,6… 110,21… 112,08… 108,4…
outs…
Weig…
ADSs 117,3… 114,51… 116,30… 112,7…
outs…
Exhibit 99.1
Select Condensed Consolidated Balance Sheet Data (U.S. GAAP)
(Amounts in thousands of U.S. Dollars)
As of
September 30, December 31,
2026 2025
Assets: (unaudited) (audited)
──────────────────────────────────────────────────────────────────────────────
Cash, cash
equivalents and $ 5,866,314 $ 4,609,647
restricted
cash
Accounts receivable, 1,092,535 865,080
net
Inventories 807,922 608,227
Property, plant and 1,647,231 1,641,678
equipment, net
Total assets $ 9,875,925 $ 8,188,573
Liabilities and
equity:
Accounts payable $ 496,879 $ 479,035
Accrued expenses and 1,342,646 1,109,120
other payables
R&D cost share — 64,345
liability
Sale of future 912,581 906,956
royalty liability
Debt 1,074,081 1,019,206
Total liabilities 4,055,531 3,827,379
Total equity $ 5,820,394 $ 4,361,194
Exhibit 99.1
Select Condensed Consolidated Statements of Cash Flows (U.S. GAAP)
(Amounts in thousands of U.S. Dollars)
Three Nine
Months Months
Ended Ended
Septem… Septe…
30, 30,
2026 2026
(unaud… 2025 (unau… 2025
──────────────────────────────────────────────────────────────────────────────
Cash,
cash
equi…
and
rest… $ 5,280… $ 2,786,… $ 4,609,… $ 2,638…
cash
at
begi…
of
peri…
Net
cash
prov… 508,7… 402,553 1,172,… 710,2…
by
oper…
acti…
Net
cash
used -35,7… -49,274 -130,6… -237,…
in
inve…
acti…
Net
cash
prov… 102,1… 961,272 164,772 962,5…
by
fina…
acti…
Net
effe…
of
fore… 10,499 9,905 49,655 36,862
exch…
rate
chan…
Net
incr…
in
cash,
cash 585,6… 1,324,… 1,256,… 1,471…
equi…
and
rest…
cash
Cash,
cash
equi…
and
rest… $ 5,866… $ 4,110,… $ 5,866,… $ 4,110…
cash
at
end
of
peri…
Exhibit 99.1
Note Regarding Use of Non-GAAP Financial Measures
BeOne provides certain non-GAAP financial measures, including Adjusted Cost of
Sales- Product, Adjusted Operating Expenses, Adjusted Income from Operations,
Adjusted Income Tax Expense, Adjusted Net Income, Adjusted Earnings Per Share,
Free Cash Flow and certain other non-GAAP income statement line items, each of
which include adjustments to GAAP figures. These non-GAAP financial measures are
intended to provide additional information on BeOne’s operating performance.
Adjustments to BeOne’s GAAP figures exclude, as applicable, non-cash items such
as share-based compensation, depreciation and amortization. Certain other
special items or substantive events may also be included in the non-GAAP
adjustments periodically when their magnitude is significant within the periods
incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP
current tax expense. The Company currently records a valuation allowance on its
net deferred tax assets, so there is no net impact recorded for deferred tax
effects. BeOne maintains an established non-GAAP policy that guides the
determination of what costs will be excluded in non-GAAP financial measures and
the related protocols, controls and approval with respect to the use of such
measures. BeOne believes that these non-GAAP financial measures, when considered
together with the GAAP figures, can enhance an overall understanding of BeOne’s
operating performance. The non-GAAP financial measures are included with the
intent of providing investors with a more complete understanding of BeOne’s
historical and expected financial results and trends and to facilitate
comparisons between periods and with respect to projected information. In
addition, these non-GAAP financial measures are among the indicators BeOne’s
management uses for planning and forecasting purposes and measuring BeOne’s
performance. These non-GAAP financial measures should be considered in addition
to, and not as a substitute for, or superior to, financial measures calculated
in accordance with GAAP. The non-GAAP financial measures used by BeOne may be
calculated differently from, and therefore may not be comparable to, non-GAAP
financial measures used by other companies.
Exhibit 99.1
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
(Amounts in thousands of U.S. Dollars, except for per share and per ADS data)
(unaudited)
Reco…
of
GAAP
to
adju… Three Nine
cost Months Months
of Ended Ended
sales Septem… Septe…
- 30, 30,
prod… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
cost
of $ 216,8… $ 196,510 $ 558,641 $ 526,1…
sales
-
prod…
Less: 5,596 4,261 15,442 10,195
Depr…
Less:
Amor… 23,598 1,537 26,932 8,459
of
inta…
Less: — — — 893
Other
Adju…
cost
of $ 187,7… $ 190,712 $ 516,267 $ 506,5…
sales
-
prod…
Reco…
of
GAAP
to
adju…
rese…
and
deve…
GAAP
rese… $ 660,7… $ 523,662 $ 1,814,… $ 1,530…
and
deve…
Less:
Shar… 56,474 58,839 168,866 164,9…
comp…
cost
Less: 18,142 18,919 59,400 54,291
Depr…
Adju…
rese… $ 586,1… $ 445,904 $ 1,586,… $ 1,311…
and
deve…
Reco…
of
GAAP
to
adju…
sell…
gene…
and
admi…
GAAP
sell…
gene… $ 593,4… $ 528,998 $ 1,741,… $ 1,526…
and
admi…
Less:
Shar… 76,143 81,947 224,566 221,7…
comp…
cost
Less: 13,582 12,550 40,769 32,712
Depr…
Less:
Amor… 16 17 50 45
of
inta…
Adju…
sell…
gene… $ 503,7… $ 434,484 $ 1,476,… $ 1,271…
and
admi…
Reco…
of
GAAP
to
adju…
oper…
expe…
GAAP
oper… $ 1,254… $ 1,052,… $ 3,556,… $ 3,056…
expe…
Less:
Shar… 132,6… 140,786 393,432 386,7…
comp…
cost
Less: 31,724 31,469 100,169 87,003
Depr…
Less:
Amor… 16 17 50 45
of
inta…
Adju…
oper… $ 1,089… $ 880,388 $ 3,062,… $ 2,582…
expe…
Reco…
of
GAAP
to
adju…
inco…
from
oper…
GAAP
inco… $ 418,6… $ 163,114 $ 993,624 $ 262,1…
from
oper…
Plus:
Shar… 132,6… 140,786 393,432 386,7…
comp…
cost
Plus: 37,320 35,730 115,611 97,198
Depr…
Plus:
Amor… 23,614 1,554 26,982 8,504
of
inta…
Plus: — — — 893
Other
Adju…
inco… $ 612,2… $ 341,184 $ 1,529,… $ 755,4…
from
oper…
Reco…
of
GAAP
to
adju…
inco…
tax
expe…
GAAP
inco… $ 25,654 $ 22,323 $ 132,964 $ 47,182
tax
expe…
Plus:
Disc… 11,527 926 -41,847 9,663
tax
items
Plus:
Inco…
tax
effe… 27,995 17,044 68,668 45,747
of
non-…
adju…
Adju…
inco… $ 65,176 $ 40,293 $ 159,785 $ 102,5…
tax
expe…
Exhibit 99.1
Reco…
of Three Nine
GAAP Months Months
to Ended Ended
adju… Septem… Septe…
net 30, 30,
inco… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
net $ 384,7… $ 124,841 $ 849,070 $ 220,4…
inco…
Plus:
Shar… 132,6… 140,786 393,432 386,7…
comp…
expe…
Plus: 37,320 35,730 115,611 97,198
Depr…
Plus:
Amor… 23,614 1,554 26,982 8,504
of
inta…
Plus: — — — 893
Other
Plus:
Impa…
of — 18,722 — 34,216
equi…
inve…
Plus:
Disc… -11,5… -926 41,847 -9,663
tax
items
Plus:
Inco…
tax
effe… -27,9… -17,044 -68,668 -45,7…
of
non-…
adju…
Adju…
net $ 538,7… $ 303,663 $ 1,358,… $ 692,6…
inco…
Reco…
of
GAAP
to
adju…
EPS -
basic
GAAP
earn…
per $ 0.26 $ 0.09 $ 0.58 $ 0.16
share
-
basic
Plus:
Shar… 0.09 0.10 0.27 0.27
comp…
expe…
Plus: 0.03 0.02 0.08 0.07
Depr…
Plus:
Amor… 0.02 0.00 0.02 0.01
of
inta…
Plus: 0.00 0.00 0.00 0.00
Other
Plus:
Impa…
of 0.00 0.01 0.00 0.02
equi…
inve…
Plus:
Disc… -0.01 0.00 0.03 -0.01
tax
items
Plus:
Inco…
tax
effe… -0.02 -0.01 -0.05 -0.03
of
non-…
adju…
Adju…
earn…
per $ 0.36 $ 0.21 $ 0.93 $ 0.49
share
-
basic
Reco…
of
GAAP
to
adju…
EPS -
dilu…
GAAP
earn…
per $ 0.25 $ 0.08 $ 0.56 $ 0.15
share
-
dilu…
Plus:
Shar… 0.09 0.09 0.26 0.26
comp…
expe…
Plus: 0.02 0.02 0.08 0.07
Depr…
Plus:
Amor… 0.02 0.00 0.02 0.01
of
inta…
Plus: 0.00 0.00 0.00 0.00
Other
Plus:
Impa…
of 0.00 0.01 0.00 0.02
equi…
inve…
Plus:
Disc… -0.01 0.00 0.03 -0.01
tax
items
Plus:
Inco…
tax
effe… -0.02 -0.01 -0.05 -0.03
of
non-…
adju…
Adju…
earn…
per $ 0.35 $ 0.20 $ 0.90 $ 0.47
share
-
dilu…
Reco…
of
GAAP
to
adju…
earn…
per
ADS -
basic
GAAP
earn…
per $ 3.38 $ 1.13 $ 7.58 $ 2.03
ADS -
basic
Plus:
Shar… 1.17 1.28 3.51 3.56
comp…
expe…
Plus: 0.33 0.32 1.03 0.90
Depr…
Plus:
Amor… 0.21 0.01 0.24 0.08
of
inta…
Plus: 0.00 0.00 0.00 0.01
Other
Plus:
Impa…
of 0.00 0.17 0.00 0.32
equi…
inve…
Plus:
Disc… -0.10 -0.01 0.37 -0.09
tax
items
Plus:
Inco…
tax
effe… -0.25 -0.15 -0.61 -0.42
of
non-…
adju…
Adju…
earn…
per $ 4.74 $ 2.76 $ 12.12 $ 6.38
ADS -
basic
Exhibit 99.1
Reconc…
of GAAP
to Three Nine
adjust… Months Months
earnin… Ended Ended
per ADS September Septemb…
- 30, 30,
diluted 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
earnin…
per ADS $ 3.28 $ 1.09 $ 7.30 $ 1.96
-
diluted
Plus:
Share-… 1.13 1.23 3.38 3.43
compen…
expens…
Plus: 0.32 0.31 0.99 0.86
Deprec…
Plus:
Amorti… 0.20 0.01 0.23 0.08
of
intang…
Plus: 0.00 0.00 0.00 0.01
Other
Plus:
Impair…
of 0.00 0.16 0.00 0.30
equity
invest…
Plus:
Discre… -0.10 -0.01 0.36 -0.09
tax
items
Plus:
Income
tax
effect -0.24 -0.15 -0.59 -0.41
of
non-GA…
adjust…
Adjust…
earnin…
per ADS $ 4.59 $ 2.65 $ 11.68 $ 6.14
-
diluted
1. Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the
relevant tax jurisdiction. Please note that the Company currently records a
valuation allowance on its net deferred tax assets, so there is no net impact
recorded for deferred tax effects.
Three Nine
Months Months
Free Ended Ended
Cash Septem… Septe…
Flow 30, 30,
(Non… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
prov…
by $ 508,7… $ 402,553 $ 1,172,… $ 710,2…
oper…
acti…
(GAA…
Less:
Purc…
of
prop… -35,1… -48,084 -103,4… -148,…
plant
and
equi…
Free
Cash $ 473,5… $ 354,469 $ 1,069,… $ 561,9…
Flow
(Non…
Reconciliation of GAAP Operating
Income
Guidance to Non-GAAP
Operating Income Guidance for
Full Year
2026
-Unaudited
GAAP operating income 1,200,000 — 1,300,000
Plus: Adjustments to arrive at 700,000 — 700,000
Non-GAAP1
Non-GAAP operating income 1,900,000 — 2,000,000
1. The non-GAAP adjustments are based on actual results through the first nine
months of 2026 and best available information at this time related to similar
items for the remainder of the year.